The term "diffuse interstitial lung disease" (ILD) encompasses a heterogeneous group of diseases with common clinical, radiological, and histological features that may occur in association with autoimmune processes, such as rheumatoid arthritis (RA), or without known cause. Although a recently published prevalence of ILD in RA of around 5% has been reported, the prevalence, as well as the clinical and histological characteristics of these diseases show large variability.1 Differences are due to, among other reasons, its often-subclinical nature, the different populations studied, and the diagnostic methods used. Risk factors for the development of ILD in RA include older age, male sex, smoking, and seropositivity for rheumatoid factor and anti-cyclic citrullinated peptide antibodies.2 The predominant symptoms of ILD are exertional dyspnoea and chronic dry cough. In addition, up to 50% of patients also have gastro-oesophageal reflux disease (GORD).(3) ILD is one of the main causes of morbidity and mortality in RA, with an estimated median survival of 3-7 years, comparable to some neoplastic diseases.1,3 Dyspnoea and cough cause significant functional impairment which, together with poor prognosis, favours the onset of depressive symptoms and loss of quality of life.4,5
The recommendations of the Spanish Society of Rheumatology (SER) and the Spanish Society of Pneumology and Thoracic Surgery (SEPAR) establish the need for multidisciplinary therapeutic management in patients with RA-associated ILD,(6) an aspect that has been repeatedly pointed out by several authors.3,7 In fact, the National Institute for Health and Care Excellence (NICE) has underlined the importance of specialist nursing in the management of patients with idiopathic pulmonary fibrosis, a type of ILD, as have the European Alliance of Associations for Rheumatology (EULAR) recommendations for the management of patients with RA-associated ILD and also the 2018 EULAR recommendations on the role of nursing in the management of chronic inflammatory arthritis.8,9 Responsibilities may include: patient and family education, assessment of symptoms (dyspnoea, fatigue, cough, and psychological distress) and comorbidities, coordination with other healthcare professionals, participation in research projects, addressing questions about severity, progression, diagnostic tests and pharmacological and non-pharmacological treatment options, and advice on support groups and other resources.4,5,7
Despite the importance of multidisciplinary treatment, the reality is that there are no practical guidelines on the specific aspects that nursing professionals face on a daily basis in the management and follow-up of patients with PIDD. Nurses assessing patients with RA-ILD are part of a healthcare team in close collaboration with the patient and family/significant others, the rheumatologist and pulmonologist, both ideally located in multidisciplinary units. Unfortunately, at present there is no speciality in rheumatology or pulmonology nursing. With these considerations in mind, OpenReuma has promoted the development of a document of recommendations, based on evidence or expert opinion, to help nurses improve the management and follow-up of patients with PIDD.
The usual methodological approach for evidence-based consensus was used, including nominal group, systematic review (SR), and Delphi survey. The study was conducted in the following successive phases: 1) nominal group with an expert panel and patient interview; 2) SRs; 3) consensus meeting for the development of recommendations; and 4) Delphi voting on the degree of agreement. By its nature, the project was exempt from the need for approval by a research ethics committee. However, it was guided in accordance with the principles set out in the Declaration of Helsinki, applicable Good Clinical Practice regulations and current legislation on confidentiality.
To address all aspects of interest, a multidisciplinary panel of 13 people - 7 rheumatology nurses, 2 rheumatologists, 1 pulmonologist, 1 psychologist, 1 physiotherapist and occupational therapist and 1 patient with ILD - was formed. In a first meeting of the panel, the guidelines of the document, the scope, the users, and the structure were defined. In addition, the points on which to explore the evidence were identified. The panel met twice and was kept informed throughout the development of the project via the Miro® platform.
The clinical questions defined by the panel were transformed into the PICOt epidemiological format so that they could be answered by systematic literature review (Table 1). We evaluated the efficacy and safety of pulmonary rehabilitation and non-pharmacological interventions to improve two typical problems of ILD: refractory cough and GORD.
The reviews conducted were hierarchical, i.e., for each question, existing SR papers were first identified and assessed for bias. We only proceeded to search for primary studies in cases where the evidence was not sufficiently robust, direct, and consistent to answer the question posed. A search strategy was established for each question including terms related to ILD, pulmonary rehabilitation, refractory cough, or GORD, both MeSH and free text, filtered by study type "systematic review" (Table 2). Articles were peer-selected by title and abstract using Rayyan® software and then read in detail to check for eligibility.
The methodological quality of the reviews selected was assessed using the AMSTAR-2 tool, excluding those whose quality was low, very low, or critically low.10 If the evidence was not sufficiently solid, direct, and consistent to answer a specific question, a search for primary studies was carried out. The methodological assessment was performed using the Cochrane Rob 2 risk of bias tool and Jadad's scale for the risk of bias.11,12 In order to facilitate informed decisions by the panel, tables including information from the selected studies were prepared using the GRADE methodology.13 For this purpose, the most relevant results were selected and the level of evidence for each specific question was assigned. The GRADE system classifies the quality of evidence into four levels: high, moderate, low, and very low.
Once the literature review was completed and based on the issues raised at the first meeting, the steering group produced a draft of the recommendations to work on. These recommendations, together with their evidence, were presented at a second meeting of the panel for discussion and consensus editing. For each of the proposed recommendations a first vote was taken during the meeting. In this first vote, only those recommendations were voted for or against. Consensus was only reached for those recommendations that achieved 65% in favour. Adjustments were then made to the wording to reflect all the panel's perspectives. In addition, recommendations not proposed by the steering group were added during the meeting, following the same methodology. All the panel's discussions were recorded in minutes that served as the basis for the final document.
The recommendations obtained at the consensus meeting were transformed into the items of a Delphi survey. This Delphi was answered by the panel members and sent to the OpenReuma members (rheumatologists and nurses), as potential users of the recommendations. In the Delphi (conducted with Welphi®), each item was presented with a summary of the evidence. The degree of agreement was scored on a scale from 0 (strongly disagree) to 10 (strongly agree). In a first round, corrections to the text were allowed. If a recommendation did not require corrections and reached more than 75% agreement, it was not passed to the second round.
The results of the SRs are presented for each research question: 1) Efficacy of pulmonary rehabilitation in ILD. Twenty-four SRs were identified of which 4 were finally included for detailed reading; 2) Efficacy of non-pharmacological interventions for the treatment of refractory cough. This search was not narrowed down by ILD, and therefore included refractory cough of any cause. Twenty SRs were identified, of which two were finally included for detailed reading; and 3) Efficacy of non-pharmacological interventions for the treatment of GORD. This search was also not narrowed by ILD and therefore included reflux of any cause. Eight SR were identified, of which only one was selected for detailed reading, although it did not include patients with GORD. The flow chart of the three research questions is presented in Figure 1.
A total of 15 recommendations were formulated for which a summary of the evidence obtained is presented. Table 3 shows the complete list of recommendations with their level of evidence according to GRADE and the degree of agreement.
Only one of the 12 recommendations was based on the SRs, while the rest are based on expert opinion, although they are easy to justify.
[i]Abbreviations: ILD, interstitial lung disease; RA, rheumatoid arthritis; NA, not applicable; PROMs, patient-reported outcomes. * GRADE (Very High, High, Moderate, Low, Very Low). Not applicable (NA) when there is no systematic review, but it is based on expert consensus; † After the second Delphi round.
R1. Screening for comorbidities should be performed. Patients with RA should have access to a nurse with knowledge in rheumatic diseases and related diseases, among which ILD is a very relevant one. RA is a chronic inflammatory disease with significant associated comorbidity that has a major impact on patients' functional status, outcome, and quality of life.14,15 Therefore, comorbidity management in these diseases is of particular importance. Consensus documents have been developed with specific recommendations for the assessment and management of comorbidity in RA,16 although the pressure of care may be a limiting factor in following these recommendations. To facilitate the management of comorbidity in these patients, specific checklists can be used, both for healthcare professionals and for the patients themselves.17 The role of nursing in comorbidity management has been emphasised by several authors,16,18,19 as well as by the EULAR recommendations on the role of nursing in chronic inflammatory arthritis published in 2018.9
R2. The nurse should have the training to assess and screen for signs and symptoms of ILD in patients with RA. The SER-SEPAR recommendations on ILD state that patients with RA and respiratory symptoms or auscultation of velcro-like crackles should be systematically screened for ILD.6 In addition, the EULAR recommendations for nurses stress that "some tasks, traditionally performed by rheumatologists and physiotherapists, such as joint examination, and assessment of signs and symptoms can be learned and performed by nurses with minimal training".9 It would therefore be advisable to implement nursing training for the correct identification of signs and symptoms associated with ILD, e.g., perform pulmonary auscultation, and interpret the meaning of respiratory function tests. Assessment of dyspnoea by nurses is a simple task that is performed quickly and increases the confidence of the nurse by improving the efficiency of the patient-centred model. Nurses are aware of the importance of routinely measuring breathlessness and standardising this process.20 It is recommended to use the modified Medical Research Council (mMRC) scale, a very simple scale consisting of 5 levels ranging from 0 (no dyspnoea) to 5 (disabling dyspnoea).21
R3. Adherence to treatment should be assessed on a regular basis. Patient education improves adherence to treatment.(9) Although there are no specific recommendations on the type of intervention to be applied to improve adherence, the EULAR recommendations on adherence to treatment state that all professionals involved in the management of patients with rheumatic and musculoskeletal diseases should promote adherence to treatment and use tailored strategies.22 Similarly, they insist on the need to assess adherence on a regular basis, based on open-ended questions, especially when the disease is not well controlled. In these recommendations there are useful examples and checklists to adapt to the rheumatology nursing practice.
R4. The nurse must collaborate in the periodic monitoring of treatment safety. Nursing plays a key role in pharmacovigilance activities, improving patient safety and reducing treatment costs. The nurse is the healthcare professional who administers the medicines and usually follows the patient's progress first-hand and is therefore able to identify possible adverse reactions. However, the reporting of adverse reactions is exceptionally low.23 The results of a SR have shown that, despite the positive attitude of nursing professionals towards pharmacovigilance activities, their level of knowledge and practice lacks adequate competence, with lack of training being the most important obstacle;24 therefore, continued training of professionals to become competent in pharmacovigilance activities should be ensured, and qualitative studies aimed at discovering new ways to improve involvement in these processes should be promoted.
R5. The patient should be educated in the early detection of adverse effects resulting from treatment. The first EULAR recommendation on the role of nursing in chronic inflammatory arthritis states that patients should have access to a nurse for needs-based education to improve knowledge and management of their disease.9
R6. ILD-specific aspects should be included in the health education programme for patients with RA. Patient education should fulfil different activities aimed at aspects related to health promotion, abandonment of harmful habits, treatment, warning signs of complications, exercise, to foster patient independence and self-management of their disease. Educational activities are applicable at the individual level, e.g., through the use of PROMs (Patient-reported outcome measures), or at the group level and should also include family members. Educational activities should be coordinated between the pulmonology and rheumatology units.
R7. The patient should be counselled and supported in smoking cessation. Several studies have identified smoking as a risk factor for the development of ILD, although no direct relationship with mortality has been observed.2,25-28 Smoking cessation counselling is of paramount importance in these patients.(3) In this regard, it is important to highlight the usefulness of the smoking cessation units that exist in the various Spanish autonomous communities. These units are linked to hospitals and primary care teams and their coverage varies from one region of Spain to another. On the other hand, the guidance and monitoring of patients by nurses with specific training can be useful, although the evidence on the effectiveness of behavioural support, provided by nurses, to motivate and maintain abstinence from smoking is moderate.29
R8. The rheumatology nurse must educate the patient on infection prevention and identification. Patients with ILD are at increased risk of infection due to a combination of factors, such as the lung disease itself, immunosuppressive treatment, and immune system alterations,2,4 and is a major cause of mortality.1 It is therefore essential to maintain vigilance for warning signs or suspected infection and to encourage routine vaccination against influenza and pneumococcus, as established in the SER-SEPAR recommendations.(6) Preventive measures against infection are essential in patients’ protection. The nurse can reuse information on the internet, such as that available on MedlinePlus (https://medlineplus.gov/spanish/infectiousdiseases.html) or the American CDC (https://www.cdc.gov/ncbddd/spanish/sicklecell/healthyliving-prevent-infection.html), or request brochures from the hospital's Preventive Medicine Service to have available for consultation. Vaccination is usually performed at primary care following recommendations made by pulmonologists or rheumatologists.
R9. In case of reflux or orthopnoea, it may be recommended that the head of the bed be elevated. The existence of a link between GORD and various lung diseases underlines the importance of using measures that can reduce reflux with its possible effect on dyspnoea and the occurrence of exacerbations.30,31 A SR was found on the effect of head-of-bed elevation in patients with GORD, although it did not specifically include patients with ILD or RA. The results of this article showed that elevating the head of the bed, or sleeping with a wedge under a pillow, improves GORD symptoms, with a very limited impact on the reduction of reflux episodes. However, this review has an elevated risk of bias and high heterogeneity, thus a very low level of evidence.32
R10. It is recommended to complement the assessment of patients with ILD by specific PROMs. PROMs are objective measures of the patient's perception of different aspects of the disease. Since the impact of ILD on the patient's life is so important, the use of PROMs is essential to obtain a true approximation of the impact of the disease and its treatments from the patient's perspective. In addition, they are especially useful to improve physician and patient satisfaction, efficiency, communication, as well as decision making. In ILD, PROMs can be used primarily to assess symptoms (dyspnoea, cough, fatigue), quality of life, and impact of treatment. Symptom assessment, such as dyspnoea, can be done with the modified Medical Research Council (mMRC) scale, as previously discussed.(21) With regard to quality of life, validated questionnaires for patients with ILD, such as the Saint George Respiratory Questionnaire (SGRQ-I),33 or the King's Brief Interstitial Lung Disease Questionnaire (K-BILD) can be used.34 Finally, the psychological impact can be measured using the Hospital Anxiety and Depression Scale (HADS), or the Beck Depression Inventory (BDI).35 A review on the use of PROMs in ILD, published in 2021, affirms the need to use instruments specifically designed for ILD and properly validated, and also sets out a series of recommendations for their use.36
R11. If frailty is suspected, it should be confirmed by a validated instrument. Frailty is defined as a physiological state of increased vulnerability to stressors due to decreased physiological reserves. Cohort studies have shown that about half of all patients with ILD have frailty and its importance lies in its predictive role in disability, hospitalisation, and mortality.37,38 Two models of frailty have been described; Fried's model based on biomedical factors,39 and the Rockwood's model based with a more holistic definition including psychosocial and environmental factors.40 Assessment of frailty is important for the possibility of intervention. However, although multiple instruments exist, not all of them are validated. Fried's model is the most widely accepted and defines frailty by the presence of at least 3 of the following criteria: unintentional weight loss of 4.5 kg in the last year, subjective feeling of exhaustion (feeling unusually tired in the last month), weakness with objective lack of strength, decreased walking speed and low physical activity. The consensus document on frailty and falls prevention in the elderly, of the Ministry of Health and Social Affairs of 2014 proposes the SHARE-FI scale,41 validated in the Spanish population, based on the Fried criteria and applicable to non-institutionalised patients.42 There are free access calculators for this scale, differentiated by sex, at https://sites.google.com/a/tcd.ie/share-frailty-instrument-calculators/. On the other hand, a scale has been developed in Spain to measure the biological characteristics of frailty, The Frailty Trait Scale (FTS), based on Fried's model, although it also incorporates the framework proposed by Rockwood. It consists of 12 items grouped into 7 dimensions: energy balance-nutrition, physical activity, nervous system, vascular system, strength, endurance, and walking speed. This scale has predictive value for mortality in people over 80 years of age, and for hospitalisations in people under 80.43
R12. The nurse must identify available resources for referral of complicated psychosocial cases. Appropriate management of psychosocial problems improves health outcomes and quality of life for patients. The nurse is one of the closest professionals to the patient, and therefore plays a fundamental role in the detection and referral of those with psychosocial problems.
This paper presents a series of recommendations, based on the best available evidence and the opinion of a multidisciplinary group of experts, to assist nursing professionals in the management and follow-up of patients with RA-ILD. In general, existing guidelines or recommendations, such as those of SER-SEPAR, are purely clinical and do not include specific information for nurses. On the other hand, the high complexity of patients with RA-ILD requires adapting the available evidence to the context of the rheumatology nurse by developing specific recommendations to improve patient management in complex situations in which the nurse can play a role. With these considerations, twelve recommendations for the management of patients with RA-ILD by the rheumatology nurse have been established. Four recommendations are about assessment (identification), four about education (prevention), and four about of risk management (detection). Only one of the recommendations was based on available evidence, with a very low level of evidence; the rest were based on expert opinion, so the level of evidence does not apply. The degree of agreement of the recommendations ranged from 77% to 100%.
The assessment of possible lung involvement in RA patients is very important, as the occurrence of ILD carries a worse prognosis and should be done in a multidisciplinary way (integrated clinical diagnostic model).6 This is the setting for recommendations R1 (screening for comorbidities), R2 (assess and screen for signs and symptoms of ILD in patients with RA), R10 (use of specific PROMS), and R11 (assessment of frailty). Patient education is a key tool to promote self-management, self-efficacy, and appropriate coping with the disease in order to facilitate independence,44 and a major role of nursing. This aspect is reflected in recommendations R5 (education to detect adverse events), R6 (education on specific aspects of ILD), R7 (importance of smoking cessation), and R8 (need to identify and prevent infections).
Risk management represents the set of pharmacovigilance activities and interventions designed to identify, characterise, and prevent or minimise the risks of medicines and to evaluate the effectiveness of these interventions. Risk management can occur at different points during treatment: before treatment initiation, during follow-up, and in the assessment of potential undesirable effects that may occur.45 Two recommendations address this aspect, R3 (referring to the need to regularly assess adherence to treatment), and R4 (on the collaboration of the nurse in the periodic monitoring of treatment safety). Recommendation R9, referring to the efficacy of the bedside in case of reflux, refers to the effectiveness of an intervention to reduce risk of complications and was the only evidence-based recommendation, although with a very low level according to GRADE. Recommendation R12, referring to the identification and referral of patients with psychosocial problems, belongs to the context of risk management in special situations.
The following three recommendations were rejected in the second round of the Delphi:
“The nurse must have a basic knowledge of oxygen therapy and CPAP in order to be able to answer the patient's questions”.
“Patient access to respiratory rehabilitation units should be facilitated”; this recommendation had 71% agreement and was evidence-based, although with a very low level of evidence.
“In case of refractory cough, in addition to pharmacological measures, speech rehabilitation may be considered”; the level of agreement for this recommendation was very low, 59%, although it was evidence-based, with a very low level of evidence.
Unfortunately, the Delphi panel was very clear in excluding these recommendations. We cannot but reflect what happened, given that the methodology was established a priori and approved by all. Among the limitations of this work, it should be noted that all but one of the recommendations were based on expert opinion due to the lack of specific studies. In addition, it is important to note that the recommendations rejected in the second round were evidence-based, although their level of evidence was very low. One explanation for the lack of studies on the topics of the recommendations may have to do with the majority of resources being allocated to projects related to the therapeutic efficacy of specific drugs. On the other hand, the rejection of the three aforementioned recommendations could be related to the lack of specific training in ILD by nurses and the belief of overlapping roles with other health professionals. The main strength of this study is the participation of a multidisciplinary team of professionals with extensive experience in the management of patients with RA-ILD and a great interest in this topic.
In conclusion and considering the fundamental role of nursing in the management and follow-up of patients, this document presents a series of recommendations to improve the health outcomes of patients with RA-ILD. Nursing knowledge and implementation of these recommendations can facilitate the follow-up and improve the prognosis of patients with rheumatoid arthritis who present with diffuse interstitial lung disease.
1 Sparks JA, Jin Y, Cho SK, Vine S, Desai R, Doyle TJ, et al. Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patients. Rheumatol (Oxford). 2021; 60(8):3689-98.
JA Sparks Y Jin SK Cho S Vine R Desai TJ Doyle Prevalence, incidence and cause-specific mortality of rheumatoid arthritis-associated interstitial lung disease among older rheumatoid arthritis patientsRheumatol (Oxford)202160836893698
2 Spagnolo P, Lee JS, Sverzellati N, Rossi G, Cottin V. The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung Disease. Arthritis Rheumatol. 2018; 70(10):1544-54.
P Spagnolo JS Lee N Sverzellati G Rossi V Cottin The Lung in Rheumatoid Arthritis: Focus on Interstitial Lung DiseaseArthritis Rheumatol2018701015441554
6 SER-SEPAR. Recomendaciones SER-SEPAR sobre el manejo de la Enfermedad Pulmonar Intersticial Difusa asociada a la Artritis Reumatoide. 2022. (cited 27 Sept 2022). Available from: Available from: https://www.ser.es/recomendaciones-ser-separ-sobre-diagnostico-y-tratamiento-de-la-enfermedad-pulmonar-intersticial-difusa-epid-asociada-a-la-artritis-reumatoide-ar/ .
SER-SEPAR Recomendaciones SER-SEPAR sobre el manejo de la Enfermedad Pulmonar Intersticial Difusa asociada a la Artritis Reumatoide.2022cited 27 Sept 2022Available from: https://www.ser.es/recomendaciones-ser-separ-sobre-diagnostico-y-tratamiento-de-la-enfermedad-pulmonar-intersticial-difusa-epid-asociada-a-la-artritis-reumatoide-ar/
8 (NICE) NIoHaCE. Idiopathic pulmonary fibrosis in adults: diagnosis and management. 2017 (cited 27 Sept 2022). Available from: Available from: https://www.nice.org.uk/guidance/cg163 .
(NICE) NIoHaCE Idiopathic pulmonary fibrosis in adults: diagnosis and management2017cited 27 Sept 2022Available from: https://www.nice.org.uk/guidance/cg163
9 Bech B, Primdahl J, van Tubergen A, Voshaar M, Zangi HA, Barbosa L, et al. 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritis. Ann. Rheum. Dis. 2020; 79(1):61-8.
B Bech J Primdahl A van Tubergen M Voshaar HA Zangi L Barbosa 2018 update of the EULAR recommendations for the role of the nurse in the management of chronic inflammatory arthritisAnn. Rheum. Dis20207916168
10 Shea BJ, Reeves BC, Wells G, Thuku M, Hamel C, Moran J, et al. AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or both. BMJ. 2017;358:j4008.
BJ Shea BC Reeves G Wells M Thuku C Hamel J Moran AMSTAR 2: a critical appraisal tool for systematic reviews that include randomised or non-randomised studies of healthcare interventions, or bothBMJ2017358
11 Higgins J SJ, Page M, Elbers R, Sterne J. Chapter 8: Assessing risk of bias in a randomized trial. In: Higgins JPT TJ, Chandler J, Cumpston M, Li T, Page MJ, Welch VA, editor. Cochrane Handbook for Systematic Reviews of Interventions version 6.3; 2022.
SJ Higgins J M Page R Elbers J Sterne Chapter 8: Assessing risk of bias in a randomized trial JPT TJ Higgins J Chandler M Cumpston T Li MJ Page VA Welch Cochrane Handbook for Systematic Reviews of Interventions6.32022
12 Jadad AR, Moore RA, Carroll D, Jenkinson C, Reynolds DJ, Gavaghan DJ, et al. Assessing the quality of reports of randomized clinical trials: is blinding necessary? Control Clin. Trials. 1996; 17(1):1-12.
AR Jadad RA Moore D Carroll C Jenkinson DJ Reynolds DJ Gavaghan Assessing the quality of reports of randomized clinical trials: is blinding necessary?Control Clin. Trials1996171112
13 Schünemann H, Brożek J, Guyatt G, Oxman A. GRADE handbook for grading quality of evidence and strength of recommendations. 2013 (cited 27 Sept 2022). Available from: Available from: https://gdt.gradepro.org/app/handbook/handbook.html.
H Schünemann J Brożek G Guyatt A Oxman GRADE handbook for grading quality of evidence and strength of recommendations2013cited 27 Sept 2022Available from: https://gdt.gradepro.org/app/handbook/handbook.html.
14 An J, Nyarko E, Hamad MA. Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritis. Clin. Rheumatol. 2019; 38(10):2717-26.
J An E Nyarko MA Hamad Prevalence of comorbidities and their associations with health-related quality of life and healthcare expenditures in patients with rheumatoid arthritisClin. Rheumatol2019381027172726
16 Loza E, Lajas C, Andreu JL, Balsa A, Gonzalez-Alvaro I, Illera O, et al. Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritis. Rheumatol Int. 2015; 35(3):445-58.
E Loza C Lajas JL Andreu A Balsa I Gonzalez-Alvaro O Illera Consensus statement on a framework for the management of comorbidity and extra-articular manifestations in rheumatoid arthritisRheumatol Int2015353445458
17 Castaneda S, Gonzalez C, Villaverde V, Lajas Petisco C, Castro MC, Jirout F, et al. Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECOAI Project. Reumatol. Clin. (Engl Ed). 2022; 18(2):114-23.
S Castaneda C Gonzalez V Villaverde C Lajas Petisco MC Castro F Jirout Development and feasibility of 4 checklists for the evaluation of comorbidity in patients with rheumatoid arthritis, axial spondyloarthritis and psoriatic arthritis: GECOAI ProjectReumatol. Clin. (Engl Ed).2022182114123
18 Dougados M, Soubrier M, Perrodeau E, Gossec L, Fayet F, Gilson M, et al. Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA). Ann. Rheum. Dis . 2015; 74(9):1725-33.
M Dougados M Soubrier E Perrodeau L Gossec F Fayet M Gilson Impact of a nurse-led programme on comorbidity management and impact of a patient self-assessment of disease activity on the management of rheumatoid arthritis: results of a prospective, multicentre, randomised, controlled trial (COMEDRA).Ann. Rheum. Dis201574917251733
19 Russell AM, Olive S, Lines S, Murphy A, Hocking J, Newell K, et al. Contemporary challenges for specialist nursing in interstitial lung disease. Breathe (Sheff). 2018; 14(1):36-41.
AM Russell S Olive S Lines A Murphy J Hocking K Newell Contemporary challenges for specialist nursing in interstitial lung diseaseBreathe (Sheff).20181413641
21 Perez T, Burgel PR, Paillasseur JL, Caillaud D, Deslee G, Chanez P, et al. Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary disease. Int. J. Chron. Obstruct. Pulmon. Dis. 2015 ;10:1663-72.
T Perez PR Burgel JL Paillasseur D Caillaud G Deslee P Chanez Modified Medical Research Council scale vs Baseline Dyspnea Index to evaluate dyspnea in chronic obstructive pulmonary diseaseInt. J. Chron. Obstruct. Pulmon. Dis.20151016631672
22 Ritschl V, Stamm TA, Aletaha D, Bijlsma JWJ, Bohm P, Dragoi RG, et al. 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practice. Ann. Rheum. Dis . 2021; 80(6):707-13.
V Ritschl TA Stamm D Aletaha JWJ Bijlsma P Bohm RG Dragoi 2020 EULAR points to consider for the prevention, screening, assessment and management of non-adherence to treatment in people with rheumatic and musculoskeletal diseases for use in clinical practiceAnn. Rheum. Dis2021806707713
23 Velasco-Gonzalez V, Loya-Perez L, Navarro-Garcia E, Sainz-Gil M. Reporting of suspected adverse drug reactions by nursing in Spain. An observational-descriptive retrospective study. Enferm. Clin (Engl. Ed). 2021; S1130-8621(20):30534-9.
V Velasco-Gonzalez L Loya-Perez E Navarro-Garcia M Sainz-Gil Reporting of suspected adverse drug reactions by nursing in Spain. An observational-descriptive retrospective studyEnferm. Clin (Engl. Ed)2021S1130-8621203053430539
24 Salehi T, Seyedfatemi N, Mirzaee MS, Maleki M, Mardani A. Nurses' Knowledge, Attitudes, and Practice in Relation to Pharmacovigilance and Adverse Drug Reaction Reporting: A Systematic Review. Biomed Res. Int. 2021; 6630404.
T Salehi N Seyedfatemi MS Mirzaee M Maleki A Mardani Nurses' Knowledge, Attitudes, and Practice in Relation to Pharmacovigilance and Adverse Drug Reaction Reporting: A Systematic ReviewBiomed Res. Int.202166304046630404
25 Dai Y, Wang W, Yu Y, Hu S. Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and management. Clin. Rheumatol . 2021; 40(4):1211-20.
Y Dai W Wang Y Yu S Hu Rheumatoid arthritis-associated interstitial lung disease: an overview of epidemiology, pathogenesis and managementClin. Rheumatol202140412111220
26 Salaffi F, Carotti M, Di Carlo M, Tardella M, Giovagnoni A. High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalities. Medicine (Baltimore). 2019 ;98(38):e17088.
F Salaffi M Carotti M Di Carlo M Tardella A Giovagnoni High-resolution computed tomography of the lung in patients with rheumatoid arthritis: Prevalence of interstitial lung disease involvement and determinants of abnormalitiesMedicine (Baltimore).20199838e17088
27 Zhang Y, Li H, Wu N, Dong X, Zheng Y. Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease. Clin. Rheumatol . 2017; 36(4):817-23.
Y Zhang H Li N Wu X Dong Y Zheng Retrospective study of the clinical characteristics and risk factors of rheumatoid arthritis-associated interstitial lung disease.Clin. Rheumatol2017364817823
28 Zamora-Legoff JA, Krause ML, Crowson CS, Ryu JH, Matteson EL. Patterns of interstitial lung disease and mortality in rheumatoid arthritis. Rheumatology (Oxford). 2017; 56(3):344-50.
JA Zamora-Legoff ML Krause CS Crowson JH Ryu EL Matteson Patterns of interstitial lung disease and mortality in rheumatoid arthritisRheumatology (Oxford).2017563344350
30 Casanova C, Baudet JS, del Valle Velasco M, Martin JM, Aguirre-Jaime A, de Torres JP, et al. Increased gastro-oesophageal reflux disease in patients with severe COPD. Eur. Respir J. 2004; 23(6):841-5.
C Casanova JS Baudet M del Valle Velasco JM Martin A Aguirre-Jaime JP de Torres Increased gastro-oesophageal reflux disease in patients with severe COPDEur. Respir J.2004236841845
32 Albarqouni L, Moynihan R, Clark J, Scott AM, Duggan A, Del Mar C. Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic review. BMC Fam. Pract. 2021; 22(1):24.
L Albarqouni R Moynihan J Clark AM Scott A Duggan C Del Mar Head of bed elevation to relieve gastroesophageal reflux symptoms: a systematic reviewBMC Fam. Pract.20212212424
33 Capparelli I, Fernandez M, Saadia Otero M, Steimberg J, Brassesco M, Campobasso A, et al. Translation to Spanish and Validation of the Specific Saint George's Questionnaire for Idiopathic Pulmonary Fibrosis. Arch. Bronconeumol. (Engl Ed). 2018; 54(2):68-73.
I Capparelli M Fernandez M Saadia Otero J Steimberg M Brassesco A Campobasso Translation to Spanish and Validation of the Specific Saint George's Questionnaire for Idiopathic Pulmonary FibrosisArch. Bronconeumol. (Engl Ed).20185426873
34 Patel AS, Siegert RJ, Brignall K, Gordon P, Steer S, Desai SR, et al. The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaire. Thorax. 2012.67(9):804-10.
AS Patel RJ Siegert K Brignall P Gordon S Steer SR Desai The development and validation of the King's Brief Interstitial Lung Disease (K-BILD) health status questionnaireThorax2012679804810
35 Fernández M, Rodríguez-Barreto O, Buendía-Roldán I, Aberti M, Caro F, Ipuche F. Prevalence of anxiety and depression and their relationship with clinical characteristics in patients with interstitial lung disease. J. Gerontol. Res. 2019; 8(4):505.
M Fernández O Rodríguez-Barreto I Buendía-Roldán M Aberti F Caro F Ipuche Prevalence of anxiety and depression and their relationship with clinical characteristics in patients with interstitial lung diseaseJ. Gerontol. Res201984505505
36 Kalluri M, Luppi F, Vancheri A, Vancheri C, Balestro E, Varone F, et al. Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here? Eur.Respir. Rev. 2021; 30(160).
M Kalluri F Luppi A Vancheri C Vancheri E Balestro F Varone Patient-reported outcomes and patient-reported outcome measures in interstitial lung disease: where to go from here?Eur.Respir. Rev.202130160
39 Fried LP, Tangen CM, Walston J, Newman AB, Hirsch C, Gottdiener J, et al. Frailty in older adults: evidence for a phenotype. J. Gerontol. A Biol. Sci. Med. Sci. 2001; 56(3):M146-56.
LP Fried CM Tangen J Walston AB Newman C Hirsch J Gottdiener Frailty in older adults: evidence for a phenotypeJ. Gerontol. A Biol. Sci. Med. Sci2001563M146M156
41 Ministerio de Sanidad. Documento de consenso sobre prevención de fragilidad y caídas en la persona mayor 2014. Available from: https://www.sanidad.gob.es/ca/profesionales/saludPublica/prevPromocion/Estrategia/docs/Fragilidad/FragilidadyCaidas_personamayor.pdf.
Ministerio de Sanidad Documento de consenso sobre prevención de fragilidad y caídas en la persona mayor2014https://www.sanidad.gob.es/ca/profesionales/saludPublica/prevPromocion/Estrategia/docs/Fragilidad/FragilidadyCaidas_personamayor.pdf
42 Romero Ortuno R. The Frailty Instrument for primary care of the Survey of Health, Ageing and Retirement in Europe (SHARE-FI): results of the Spanish sample. Rev. Esp. Geriatr. Gerontol. 2011; 46(5):243-9.
R Romero Ortuno The Frailty Instrument for primary care of the Survey of Health, Ageing and Retirement in Europe (SHARE-FI): results of the Spanish sampleRev. Esp. Geriatr. Gerontol2011465243249
43 Garcia-Garcia FJ, Carcaillon L, Fernandez-Tresguerres J, Alfaro A, Larrion JL, Castillo C, et al. A new operational definition of frailty: the Frailty Trait Scale. J. Am. Med. Dir. Assoc. 2014; 15(5):371 e7-e13.
FJ Garcia-Garcia L Carcaillon J Fernandez-Tresguerres A Alfaro JL Larrion C Castillo A new operational definition of frailty: the Frailty Trait ScaleJ. Am. Med. Dir. Assoc.2014155e7e13
45 Gomez Reino J, Loza E, Andreu JL, Balsa A, Batlle E, Canete JD, et al. Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients. Reumatol. Clin . 2011; 7(5):284-98
J Gomez Reino E Loza JL Andreu A Balsa E Batlle JD Canete Consensus statement of the Spanish Society of Rheumatology on risk management of biologic therapy in rheumatic patients.Reumatol. Clin201175284298
[5]How to cite this article: Cano L, García MJ, Mena N, Martín JM, Domínguez C, García-Díaz S, et al. Openreuma consensus on the role of nursing in the care of patients with rheumatoid arthritis and diffuse interstitial lung disease. Invest. Educ. Enferm. 2023; 40(3):e17.DOI: https://doi.org/10.17533/udea.iee.v40n3e17.